Skip to main content

Table 2 Primary and secondary outcomes

From: Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial

  Hydrocortisone
(n = 98)
Placebo
(n = 99)
Relative risk
(95 % CI)
p Valuea
Primary outcome
 Mortality at 28 days, n (%) 22 (22.5) 27 (27.3) 0.82 (0.50–1.34) 0.51
Secondary outcomes
 Mortality at 60 days, n (%) 34 (34.7) 40 (40.4) 0.86 (0.60–1.23) 0.46
 Duration of mechanical ventilation up to day 28, days 11.8 ± 7.8 13.9 ± 9.0   0.17
 Mechanical ventilation-free days to day 28 12.0 ± 9.7 9.7 ± 10.0   0.17
 Duration of vasopressor treatment,b days 4.8 ± 3.0 6.8 ± 5.7   0.16
 Renal replacement therapy, n (%) 22 (22.4) 22 (22.2) 1.01 (0.86–1.16) 1.00
 Duration of renal replacement therapy dependent,c days 8.1 ± 6.6 8.2 ± 5.2   0.94
 Alive on day 28 without organ support, n (%) 64 (65.3) 55 (55.6) 1.18 (0.94–1.48) 0.19
 Organ support-free days to day 28d 11.9 ± 9.7 9.5 ± 9.8   0.13
  1. Unless specified otherwise, data are reported as mean ± SD
  2. aFor continuous variables, p values were calculated using the Wilcoxon-Mann-Whitney test
  3. bData calculated for the patients who received vasopressors
  4. cData calculated for the patients who received renal replacement therapy
  5. dOrgan support includes the use of mechanical ventilation, vasopressors, or renal replacement therapy